BidaskClub lowered shares of Galapagos (NASDAQ:GLPG) from a sell rating to a strong sell rating in a research note released on Saturday.
Other research analysts also recently issued research reports about the company. Stifel Nicolaus lifted their price target on Galapagos from $101.00 to $120.00 and gave the company a buy rating in a report on Friday, September 15th. Morgan Stanley reiterated an overweight rating and set a $92.00 price target on shares of Galapagos in a report on Thursday, August 10th. Cowen reiterated a buy rating on shares of Galapagos in a report on Thursday, August 10th. Nomura lifted their price target on Galapagos from $108.00 to $124.00 and gave the company a buy rating in a report on Friday, August 11th. Finally, ValuEngine downgraded Galapagos from a hold rating to a sell rating in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. Galapagos has a consensus rating of Hold and an average price target of $111.00.
Galapagos (NASDAQ GLPG) opened at $85.44 on Friday. Galapagos has a twelve month low of $57.92 and a twelve month high of $104.12.
Several institutional investors and hedge funds have recently added to or reduced their stakes in GLPG. Advisors Preferred LLC bought a new stake in shares of Galapagos during the 3rd quarter worth about $105,000. New York State Common Retirement Fund bought a new stake in shares of Galapagos during the 2nd quarter worth about $166,000. Acadian Asset Management LLC bought a new stake in shares of Galapagos during the 2nd quarter worth about $166,000. Pacad Investment Ltd. bought a new stake in shares of Galapagos during the 2nd quarter worth about $168,000. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Galapagos by 156.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 1,063 shares in the last quarter. Institutional investors own 19.71% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2017/12/06/galapagos-glpg-lowered-to-strong-sell-at-bidaskclub.html.
Galapagos Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.